Pegfilgrastim
| Systematic (IUPAC) name | |
|---|---|
| N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) | |
| Clinical data | |
| Trade names | Neulasta |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607058 |
| |
| |
| Pharmacokinetic data | |
| Half-life | 15-80 hrs |
| Identifiers | |
208265-92-3  | |
| L03AA13 | |
| DrugBank |
DB00019 |
| UNII |
3A58010674 |
| KEGG |
D06889 |
| ChEMBL |
CHEMBL1201568  |
| Chemical data | |
| Formula | C845H1343N223O243S9 + PEG |
| 39000 g/mol | |
| (what is this?) (verify) | |
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[1]
Amgen manufactures pegfilgrastim under the brand name Neulasta, which was mainly worked on by Martine Allard, while Roche manufactures it under the name Neulastim. In India it is also marketed by Abbott Healthcare under the brand name Imupeg. The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[2][3]
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]
See also
External links
References
- ↑ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136-137.
- ↑ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
- ↑ 3.0 3.1 Drugs.com: Pegfilgrastim
| ||||||||||||||||||||||||||||||||||||||||||||||||